.jpg)
.png)
Article By:
President, National Lipid Association
Director, Division of Cardiology
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch School of Medicine
Park Ridge, IL
Diplomate, American Board of Clinical Lipidology
MIAMI, Fla. – (May 18, 2019) – Findings of the first patient statin use survey based on a comprehensive set of patient experiences and behavioral markers were presented today at the National Lipid Association’s (NLA) 2019 Scientific Sessions.
Newly Defined Term Lipid Specialist Aims to Formalize Medical Specialty, Enhance Public Understanding of Blood Fat Disorders and Optimal Treatment
Case Presentation:
Article By:
Physician
Family Physicians of Greeley
Greeley, CO
Diplomate, American Board of Clinical Lipidology
Patients often search the internet for medical answers and solutions before talking to their healthcare provider (HCP). This article provides practice pearls for conversing with an e-patient.
Article By:
Past President, National Lipid
AssociationConsultative Education Specialist,
Cardiovascular Risk Intervention
University of Pennsylvania Health System - Retired
Philadelphia, PA
Nurse Practitioner
Arizona Center for Advanced Lipidology
Tucson, AZ
Nurse Practitioner
Mayo Clinic
Scottsdale, AZ
Article By:
Adjunct Professor, Midwestern University
Glendale, AZ
Private Practice
Scottsdale, AZ
Diplomate, American Board of Clinical Lipidology
Article By:
Pediatric Preventive Cardiology Fellow
Pediatric Cardiology
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH
Endowed Chair, Pediatric CV Health and Risk Prevention
Diplomate, American Board of Clinical Lipidology
Cook Children’s Medical Center
Fort Worth, TX
Treasurer, Southwest Lipid Association
Division of Cardiology
Baylor Scott & White Healthcare
Texas A&M University College of Medicine
Temple, TX
Diplomate, American Board of Clinical Lipidology
Regeneron Pharmaceuticals, Inc. and Sanofi have announced that the U.S. Food and Drug Administraion (FDA) has approved Praluent® (alirocumab) to reduce the risk of heart attack, stroke and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease.
WAYLIVRA, the only therapy available for Familial Chylomicronemia Syndrome (FCS), has been authorized as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis whose response to diet and triglyceride-lowering therapy has been inadequate, according to a May 7 press release issued by Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.
MIAMI, Fla. – (May 16, 2019) – Findings of the first patient statin use survey based on a comprehensive set of patient experiences and behavioral markers were presented today at the National Lipid Association’s (NLA) 2019 Scientific Sessions.